Kezar Life Sciences, Inc. (KZR) Analyst Estimates Annual - Discounting Cash Flows
KZR
Kezar Life Sciences, Inc.
KZR (NASDAQ)
Period Ending: 2029
12-31
2028
12-31
2027
12-31
2026
12-31
2025
12-31
2024
12-31
2023
12-31
Number of Analysts 3 4 4 0 3 3 2
Estimated Revenue
Low 19.97 31.5 21 0 4 2.4 7
Average 19.97 31.5 21 0 4 2.4 7
High 19.97 31.5 21 0 4 2.4 7
Estimated EBITDA
Low 11.98 18.9 12.6 0 2.4 1.44 4.2
Average 11.98 18.9 12.6 0 2.4 1.44 4.2
High 11.98 18.9 12.6 0 2.4 1.44 4.2
Estimated EBIT
Low 11.98 18.9 12.6 0 2.4 1.44 4.2
Average 11.98 18.9 12.6 0 2.4 1.44 4.2
High 11.98 18.9 12.6 0 2.4 1.44 4.2
Estimated Net Income
Low -298.2 -651.1 -596.7 -585.7 -497.1 -1,087 -987.5
Average -298.2 -40.03 -31.4 -345.2 -488.4 -640 -987.5
High -298.2 -8.67 -8.96 -104.8 -479.8 -193.4 -987.5
Estimated SGA Expenses
Low 31.12 49.09 32.72 0 6.23 3.74 10.91
Average 31.12 49.09 32.72 0 6.23 3.74 10.91
High 31.12 49.09 32.72 0 6.23 3.74 10.91
Estimated EPS
Low -4.09 -8.93 -8.18 -8.03 -6.82 -14.91 -13.55
Average -4.09 -4.7 -4.59 -4.74 -6.7 -5.77 -13.55
High -4.09 -0.119 -0.123 -1.44 -6.58 -2.65 -13.55
discounting cash flows home logo

Discounting Cash Flows

Are you finding our services helpful? Review us on trustpilot logo Trustpilot
Have a question? Contact us
Want to become our sponsor?
Check out our Affiliate Program